0000000000140983

AUTHOR

Bolondi L.

showing 2 related works from this author

Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma.

2014

Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to lead-time bias. Data regarding lead-time for HCC are lacking. Aims of the present study were to calculate lead-time and to assess its impact on the benefit obtainable from the surveillance of cirrhotic patients. Background & Aims: Lead-time is the time by which diagnosis is anticipated by screening/surveillance with respect to the symptomatic detection of a disease. Any screening program, including surveillance for hepatocellular carcinoma (HCC), is subject to …

Malemedicine.medical_specialtyPediatricsCarcinoma HepatocellularTime FactorsHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIADiseaseGastroenterologyBiasInternal medicineOverall survivalmedicineHumansEarly Detection of CancerAgedEstimationSurveillanceHepatologybusiness.industryLiver Neoplasmsmedicine.diseasedigestive system diseasesLead time biasCirrhosisHepatocellular carcinomaFemalebusinessLead-time biasFollow-Up Studies
researchProduct

Portal Vein Thrombosis Relevance on Liver Cirrhosis: Italian Venous Thrombotic Events Registry

2016

Portal vein thrombosis may occur in cirrhosis; nevertheless, its prevalence, and predictors are still elusive. To investigate this issue, the Italian Society of Internal Medicine undertook the “Portal vein thrombosis Relevance On Liver cirrhosis: Italian Venous thrombotic Events Registry” (PRO-LIVER). This prospective multicenter study includes consecutive cirrhotic patients undergoing Doppler ultrasound examination of the portal area to evaluate the prevalence and incidence of portal vein thrombosis over a 2-year scheduled follow-up. Seven hundred and fifty-three (68 % men; 64 ± 12 years) patients were included in the present analysis. Fifty percent of the cases were cirrhotic outpatients.…

RegistrieLiver CirrhosisMaleCirrhosisHepatocellular carcinoma030204 cardiovascular system & hematologyGastroenterology0302 clinical medicineEsophageal varicesPrevalenceMedicineProspective StudiesRegistriesProspective cohort studyMultivariate AnalysiVenous ThrombosisPortal VeinAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis; Emergency Medicine; Internal MedicineMiddle AgedPortal vein thrombosisVenous thrombosisSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesSplanchnic venous thrombosisItalyLiverEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.symptomSettore SECS-S/01 - StatisticaHumanmedicine.medical_specialtyLiver CirrhosiSocio-culturaleEsophageal varicesAsymptomatic03 medical and health sciencesAnticoagulants Esophageal varices Hepatocellular carcinoma Liver failure Splanchnic venous thrombosisInternal medicineInternal MedicineHumansAgedHepatologyEsophageal varicebusiness.industryAnticoagulantLiver failureAnticoagulants; Esophageal varices; Hepatocellular carcinoma; Liver failure; Splanchnic venous thrombosis;AnticoagulantsSplanchnic venous thrombosimedicine.diseaseSurgeryProspective StudieSplanchnic venous thrombosis Anticoagulants Liver failure Hepatocellular carcinoma Esophageal varicesMultivariate AnalysisUpper gastrointestinal bleedingComplicationbusinessJournal of Hepatology
researchProduct